Mersana Therapeutics — Investor Presentation (January 2020)
27 slides from Mersana Therapeutics's investor presentation, Jan 10, 2020
Slide 1: Accelerating ADC Innovation …because patients are waiting
Accelerating ADC Innovation …because patients are waiting January 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains “forward - looking” statements within the meaning of federal securities laws . These forward - looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to managem
Slide 3: Mersana is Poised for a Transformational 2020
Mersana is Poised for a Transformational 2020 3 1 Excluding Brazil 2 Cash, Cash Equivalents, and Marketable Securities as of September 30, 2019 XMT - 1536 • First - in - class asset • Clinically - Validated • Wholly - Owned 1 • Fast - to - market strategy On Track for Near - Term Proof of Concept Fi
Slide 4: 2020 Will Be a Data Rich Year
2020 Will Be a Data Rich Year 4 o Establish proof of concept o Rapid dose escalation o Select first development candidate o Progress into IND - enabling studies 2019 ACCOMPLISHMENTS 2020 PRIORITIES x Established proof of activity & tolerability x Established preclinical proof of concept x Advanced t
Slide 5: Leveraging Novel ADC Platforms to Generate Differentiated Product Candidates
We are Leveraging our Novel ADC Platforms to Generate Differentiated Product Candidates 5 ADC Program Target Indication Platform Discovery Preclinical P1 Dose Escalation P1 Proof of Concept P2/Pivotal Study XMT - 1536 NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolaflexin XMT - 1592 NaPi2b NSCLC Aden
Slide 6: Innovative and Highly Differentiated ADC Technologies and Platforms
Efficacy without severe neutropenia, neuropathy, or ocular toxicity DolaLock Dolaflexin Improved therapeutic index vs. other platforms Dolasynthen Homogenous & Customizable Platform Immunosynthen Systemic administration with targeted immuno - stimulatory effect Innovative and Highly Differentiated A
Slide 7: XMT-1536: First-in-Class Dolaflexin ADC Targeting NaPi2b
XMT - 1536: First - in - Class Dolaflexin ADC Targeting NaPi2b
Slide 8: Leader in Targeting NaPi2b, an Ideal and Validated ADC Target
Leader in Targeting NaPi2b, an Ideal and Validated ADC Target • Broadly expressed in ovarian cancer and NSCLC adenocarcinoma ⁃ No detectable expression in squamous NSCLC ⁃ Limited expression in healthy tissues • NaPi2b is a lineage marker (not an oncogene) that transports phosphate into the cell ⁃ T
Slide 9: XMT-1536: Advancing Through Proof-of-Concept Studies in Ovarian Cancer and NSCLC Adenocarcinoma
XMT - 1536: Advancing Through Proof - of - Concept Studies in Ovarian Cancer and NSCLC Adenocarcinoma 9 Encouraging Clinical Activity Well - Tolerated • Confirmed responses and prolonged stable disease in heavily pretreated and biomarker unselected patients reported at ASCO 2019 • Expansion cohorts
Slide 10: XMT-1536 was Well-Tolerated with Most AEs Grade 0
XMT - 1536 was Well - Tolerated with Most AE’s Grade 1 - 2 10 ClinicalTrials.gov: NCT03319628 Dosing: Q3 weeks DL 4A 20 mg/m 2 (0.54 mg/kg) N=9 DL 5A 30 mg/m 2 (0.81 mg/kg) N=8 DL 6A 36 mg/m 2 (0.97 mg/kg) DL 1 3 mg/m 2 (0.081 mg/kg) N=1 DL 2 6 mg/m 2 (0.162 mg/kg) N=1 DL 3 12 mg/m 2 (0.324 mg/kg) N
Slide 11: XMT-1536 Showed Activity in Heavily Pretreated Patients, Unselected for NaPi2b
XMT - 1536 Showed Activity in Heavily Pretreated Patients, Unselected for NaPi2b 11 Data Presented at ASCO with a Data Cutoff of May 10, 2019 Response evaluable All Completed Dose Levels (OC and NSCLC Patients), N=26 Clinically Meaningful Treatment Duration > 16 weeks Clinical Activity at Doses of 2
Slide 12: XMT-1536: Significant Progress Since ASCO 2019
XMT - 1536: Significant Progress Since ASCO 2019 in Maximizing Patient Benefit and Charting Path to Registration 12 • Initiated expansion cohorts in earlier line, more homogeneous populations Earlier, More Homogeneous Patient Population Higher Dose Opportunity for Biomarker Selection • Correlating H
Slide 13: XMT-1536: Path to Pivotal Study in High Unmet Need Indications
XMT - 1536: Path to Pivotal Study in High Unmet Need Indications 13 Population Dose Current Standard of Care ORR: 4 - 12% mPFS: 3 - 4 mos mOS: 9 - 12 mos • Prior treatment with a platinum doublet and PD - 1/L1 inhibitor • Prior TKIs if targetable mutation • Up to 2 prior lines of cytotoxic therapy •
Slide 14: XMT-1592 is a Dolasynthen ADC Targeting NaPi2b
XMT - 1592 is a Dolasynthen ADC Targeting NaPi2b
Slide 15: XMT-1592 Shows Four-Fold Greater Efficacy in Lung Tumor Model
XMT - 1592 Shows Four - Fold Greater Efficacy in Lung Tumor Model 15 2X Tumor Exposure of Payload 0 7 14 21 28 35 42 49 56 63 70 0 500 1000 1500 2000 Days on study M e a n T u m o r V o l u m e S E M ( m m 3 ) Vehicle XMT-1536 @ 0.1 mg/kg [2.1 mg/kg mAb] XMT-1592 @ 0.1 mg/kg [3.0 mg/kg mAb] 0.1 mg/k
Slide 16: Leveraging NaPi2b Experience for Rapid Dose Escalation of XMT-1592
Leveraging NaPi2b Experience for Rapid Dose Escalation of XMT - 1592 16 2021 Solidify NaPi2b Leadership Leveraging insights from XMT - 1536 Biomarker Investigators Antibody Payload Patient Populations Target 2020 2020 2021 Inform Product Engine File IND Initiate Dose Escalation Achieve MTD Clinical
Slide 17: First-in-Class B7-H4 ADC Progressing into IND-Enabling Studies
First - in - Class B7 - H4 ADC Progressing into IND - Enabling Studies
Slide 18: B7-H4 Expression Ideally Suited for a DolaLock ADC
B7 - H4 Expression Ideally Suited for a DolaLock ADC • B7 - H4 is expressed on both tumor cells and immunosuppressive tumor - associated macrophages (TAMs) ⁃ Limited expression in normal tissues • A DolaLock ADC targeting B7 - H4 can exert its effect through multiple mechanisms of action: ⁃ Uptake b
Slide 19: Immunosynthen Development Candidate in 2020
Immunosynthen Development Candidate in 2020
Slide 20: Immunosynthen: Strong Rationale for a STING Agonist ADC Approach
Immunosynthen: Strong Rationale for a STING Agonist ADC Approach ADCs are suited to overcome limitations of free agonist: ⁃ Targeted delivery reduces toxicity liabilities ⁃ Improved pharmacokinetics ⁃ Accessibility to metastatic sites ⁃ No restriction on tumor type, location or size 20 Nature Review
Slide 21: Immunosynthen ADCs Show In Vivo Activity Against Multiple Targets and Immune Memory
0 7 14 21 28 0 50 100 150 200 250 Days on Re-challenge Study M e a n T u m o r V o l u m e + / - S E M ( m m 3 ) Immunosynthen ADCs Show In Vivo Activity Against Multiple Targets and Immune Memory 21 0 7 14 21 28 35 42 49 56 63 0 250 500 750 1000 Days on study M e a n T u m o r V o l u m e + / - S E
Slide 22: Immunosynthen ADC Activates STING Pathway and Induces Immune Cell Infiltration
Immunosynthen ADC Activates STING Pathway and Induces Marked Immune Cell Infiltration in Tumors 22 Cytokine expression (qPCR on FFPE samples) 0 5 10 15 20 25 12H 72H mCXCL10 0 0.4 0.8 1.2 1.6 12H 72H mIFN β 0 2 4 6 12H 72H mIL - 6 12 H 12 H 12 H 72 H 72 H mCXCL10 mIL - 6 mIFNβ Vehicle Targeted ADC C
Slide 23: Limited Induction of Serum Cytokines In Vivo by Immunosynthen ADC
Limited Induction of Serum Cytokines In Vivo by Immunosynthen ADC Despite Extended Plasma Exposure 23 CXCL10 IL - 6 CXCL1 RANTES (CCL5) 0 20 40 60 80 0 1000 2000 3000 4000 Hours 0 20 40 60 80 0 5000 10000 15000 20000 25000 Hours 0 20 40 60 80 0 2000 4000 6000 Hours 0 20 40 60 80 0 1000 2000 3000 400
Slide 24: On Track to Select First Immunosynthen ADC Development Candidate in 2020
On Track to Select First Immunosynthen ADC Development Candidate in 2020 24 Payload Molecule Drug Load Per Scaffold Charge Balance Aqueous Solubility Bioconjugation Antibody x Identified proprietary STING payload specifically designed for ADCs x Demonstrated efficacy across multiple targets in a var
Slide 25: 2020: A Transformational Year for Mersana with Multiple Data Readouts
2020: A Transformational Year for Mersana with Multiple Data Readouts 25 2020 Goals & Anticipated Milestones XMT - 1536 • Report dose escalation in 1H 2020 • Report interim data from OC and NSCLC expansion cohorts in 1H 2020 • Report more mature data from expansion cohorts in 2H 2020 XMT - 1592 • Fi
Slide 26: Positioned to Create Value for Patients and Shareholders
Positioned to Create Value for Patients and Shareholders 26 • First - in - class NaPi2b ADC • Completion of proof - of - concept studies in 2020 • Fast - to - market registration strategy XMT - 1536 • Extends NaPi2b leadership • Fast to clinical validation of preclinical differentiation XMT - 1592 •
Slide 27: Slide 27
Mersana Therapeutics — Investor Presentation (January 2020) on 6ix